We searched the NorthShore EPIC patient database to identify all patients who had undergone a liver biopsy or magnetic resonance elastography for the assessment of non-alcoholic fatty liver disease during the time period between February of 2010 and October of 2020. A chart review was performed for each patient to ascertain the correct diagnosis, and to extract clinical, demographic, laboratory, liver biopsy, and magnetic resonance elastography (MRE) data. When necessary, liver biopsies were reviewed by a trained hepato-pathologist (N.J.) to determine the fibrosis stage, using the NASH Clinical Research Network criteria[11 (link)]. Samples subclassified as fibrosis stages 1A, 1B, or 1C were combined under “stage 1”. The MRE measurements were performed using a Siemens Magnetom Aera 1.5T scanner. MRE liver stiffness measurements were stratified into five groups (0-2.9 kPa, 2.9-3.5 kPa, 3.5-4.0 kPa, 4.0-5.0 kPa, and >5.0 kPa), following published guidelines[12 (link)].